Vertex, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Christopher David Young
- Full Time Employees
- 1,900
- Sector
- Technology
- Industry
- Software - Application
- Address
- 2301 Renaissance Boulevard King of Prussia PA United States of America 19406
- IPO Date
- Jul 29, 2020
- CIK
- 0001806837
- Website
- vertexinc.com
- Similar Companies
- Business
- Vertex, Inc. is a technology company primarily engaged in providing tax compliance, tax automation, and related software solutions. The company offers a comprehensive suite of products and services including indirect tax software for managing sales and use tax, value-added tax (VAT), goods and services tax (GST), and other transactional taxes globally; automated tax determination software; tax data management solutions; cloud-based and on-premise tax compliance software; and integrated tax engines for enterprise resource planning (ERP) systems. Vertex’s product portfolio supports a range of industries including retail, manufacturing, financial services, and telecommunications, serving customers worldwide. The company also provides implementation, consulting, and support services to help businesses comply with evolving tax regulations. Founded in 1978 and headquartered in King of Prussia, Pennsylvania, Vertex operates internationally with offices and clients across North America, Europe, and Asia. Recently, Vertex has expanded its capabilities through strategic partnerships and new product launches aimed at enhancing its global tax compliance automation offerings. In the past 1-2 years, the company has focused on advancing its cloud-based tax solutions to better address digital tax complexities and cross-border tax compliance challenges. Vertex continues to invest in technology upgrades and integrations to support multinational corporations’ growing needs, positioning itself as a leader in the tax technology industry. These developments reflect Vertex’s commitment to innovation and broadening its market reach, underscoring its role in delivering advanced tax software solutions to help businesses navigate increasingly complex global tax landscapes. The company leverages its proprietary tax engine and extensive tax content database to deliver precise and scalable tax management solutions. Vertex is recognized for its strong customer support and technology-driven approach, targeting large enterprises and mid-market companies needing comprehensive tax automation and compliance tools. This dynamic business environment and Vertex’s expansions highlight the company’s strategic focus on maintaining leadership in the evolving tax technology sector through continuous product enhancement and global operational growth.
Vertex Gets FDA Nod for Expanded Use of Casgevy in SCD & TDT
Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia
US FDA approves Vertex's gene therapy for sickle cell disease in children as young as two
Dyne Therapeutics vs. Vertex Pharmaceuticals: Which Drug Innovator Stock Is a Better Buy in 2026?
Vertex Pharmaceuticals Has One Of The Widest And Most Durable Moats In Biotech
Why Vertex Stock Is Rising Today
CRISPR Therapeutics AG vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
Vertex Energy Announces 6,000 bpd Group III Base Oil Expansion Project
Vertex Pharmaceuticals: Povetacicept May Redefine Growth Narrative (Rating Upgrade)
Instruqt Becomes the First and Only Platform to Pair AI-Assisted Content Creation with Native Vertex AI, Amazon Bedrock, and GPU Environments
Vertex Has a Head Start in Non-Opioid Pain. Eli Lilly Just Spent Billions to Catch Up.
Can Vertex's Kidney Pipeline Power Its Next Growth Phase?
Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference
Madrigal Pharmaceuticals Could Become The Next Vertex
FDA Accepts Vertex's BLA for Povetacicept in IgA Nephropathy
Vertex Stock Down Nearly 8% in 3 Months: Time to Buy or Stay Cautious?
Vertex to Present at the 46th Annual William Blair Growth Stock Conference
New Vertex Research Highlights Rising Revenue Risk from IT, Tax, and Finance Misalignment
Vertex Q1 Earnings Call Highlights
Vertex: Profitability Ramps Up As Company Drives Efficiency Initiatives